Player FM - Internet Radio Done Right
46 subscribers
Checked 3d ago
Добавлено восемь лет назад
Контент предоставлен Dr Neil Love. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Dr Neil Love или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
Player FM - приложение для подкастов
Работайте офлайн с приложением Player FM !
Работайте офлайн с приложением Player FM !
Chronic Myeloid Leukemia | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia
Manage episode 460256885 series 1464352
Контент предоставлен Dr Neil Love. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Dr Neil Love или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
Featuring perspectives from Prof Andreas Hochhaus, Dr Michael J Mauro and Dr B Douglas Smith, moderated by Dr Mauro, including the following topics:
- Introduction (0:00)
- Up-Front Therapy for Chronic Myeloid Leukemia (CML) — Prof Hochhaus (2:45)
- Management of Relapsed CML, Including in Patients with a T315I Mutation — Dr Mauro (29:23)
- Tolerability and Other Practical Issues with Commonly Employed CML Therapies — Dr Smith (1:00:15)
1474 эпизодов
Manage episode 460256885 series 1464352
Контент предоставлен Dr Neil Love. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Dr Neil Love или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
Featuring perspectives from Prof Andreas Hochhaus, Dr Michael J Mauro and Dr B Douglas Smith, moderated by Dr Mauro, including the following topics:
- Introduction (0:00)
- Up-Front Therapy for Chronic Myeloid Leukemia (CML) — Prof Hochhaus (2:45)
- Management of Relapsed CML, Including in Patients with a T315I Mutation — Dr Mauro (29:23)
- Tolerability and Other Practical Issues with Commonly Employed CML Therapies — Dr Smith (1:00:15)
1474 эпизодов
Все серии
×R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
1 HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management Strategies 2:01:57
2:01:57
Прослушать Позже
Прослушать Позже
Списки
Нравится
Нравится2:01:57![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Featuring slide presentations and related discussion from Dr Joyce O'Shaughnessy, Dr Mark Pegram and Prof Peter Schmid, including the following topics: Strategies to Identify Patients with HER2-Low and HER2-Ultralow Breast Cancer (0:00) Case: A woman in her mid 50s initially presenting with ER-positive, HER2 IHC 1+ locally advanced breast cancer who experiences progression to HER2 0 metastatic disease (20:53) Case: A woman in her early 60s with ER-positive, HER2 IHC 1+ metastatic breast cancer (mBC) who experiences disease progression 8 months after starting first-line CDK4/6 and aromatase inhibitor (29:14) Expanding the Spectrum of Targeted Therapy (38:52) Case: A woman in her early 60s with HR-positive, HER2 IHC 1+ mBC who receives fifth-line T-DXd resulting in stable disease (1:04:13) Case: A woman in her early 50s with progressive HR-positive, HER2 IHC 0 mBC and an ESR1 mutation who has ultralow HER2 expression on rebiopsy of new liver lesions (1:12:35) Identification and Management of Adverse Events with T-DXd (1:20:27) Case: A woman in her late 40s with HR-positive, HER2 IHC 2+ mBC who experienced persistent low-grade nausea with T-DXd that resolved with olanzapine (1:34:02) Case: A woman in her early 60s with ER-positive, HER2 2+ mBC who received T-DXd resulting in fatigue and asymptomatic interstitial lung disease (1:48:58) CME information and select publications…
R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
1 Hepatocellular Carcinoma — Proceedings From a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI) 1:58:47
1:58:47
Прослушать Позже
Прослушать Позже
Списки
Нравится
Нравится1:58:47![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Featuring perspectives from Dr Anthony El-Khoueiry, Dr Richard S Finn, Dr Aiwu Ruth He and Dr Stacey Stein, moderated by Dr Stephen “Fred” Divers, including the following topics: Adjuvant Systemic Therapy for Early-Stage Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry Introduction (0:00) Faculty Presentation (3:08) IMbrave050: Adjuvant systemic treatment for high-risk resected HCC — Robin K (Katie) Kelley, MD and Thomas A Abrams, MD (13:43) Neoadjuvant systemic therapy for patients with borderline resectable HCC — Dr Abrams (20:15) Case: A man in his early 70s with locally advanced HCC and tumor thrombus that extends into the right atrium — Ghassan Abou-Alfa, MD, MBA (24:34) Recent Developments in the Management of Intermediate-Stage HCC — Dr Finn Faculty Presentation (31:18) EMERALD-1 and LEAP-012 trials of TACE with immunotherapy — Drs Abrams and Kelley (42:15) Systemic treatment for patients with Child-Pugh B cirrhosis and HCC — Dr Kelley (48:29) Use of immunotherapy for patients with autoimmune disorders: A man in his early 30s with active colitis and metastatic HCC receives first-line lenvatinib — Drs Abrams and Abou-Alfa (53:05) Current First-Line Therapy for Advanced HCC — Dr He Faculty Presentation (1:00:39) Selection of first-line treatment regimen for advanced HCC — Drs Abrams, Kelley and Abou-Alfa (1:12:00) Role of single-agent immunotherapy in the treatment of advanced HCC — Dr Kelley (1:18:22) Management of HCC in patients with discordant tumor markers or mixed tumor histology — Dr Abrams (1:23:03) Promising Investigational Front-Line Strategies for Advanced HCC; Selection and Sequencing of Therapy for Relapsed/Refractory HCC — Dr Stein Faculty Presentation (1:29:42) Choice of tyrosine kinase inhibitor as second-line systemic treatment for HCC; prevention, monitoring and mitigation of lenvatinib-associated side effects — Dr Kelley (1:42:59) Case: A man in his early 70s with metastatic HCC that has rapidly progressed on atezolizumab/bevacizumab — Dr Abou-Alfa (1:49:27) Supportive care measures to manage ascites in patients with HCC — Dr Abrams (1:55:20) CME information and select publications…
R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
1 EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances 1:00:02
1:00:02
Прослушать Позже
Прослушать Позже
Списки
Нравится
Нравится1:00:02![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Featuring perspectives from Dr Enriqueta Felip and Dr Helena Yu, including the following topics: Introduction (0:00) First-Line Treatment of Metastatic Disease (2:34) Adjuvant and Neoadjuvant Therapy (22:31) EGFR Exon 20 Insertion Mutations (34:21) Antibody-Drug Conjugates (42:45) CME information and select publications…
R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 2: Other Relevant Topics in EGFR Mutation-Positive NSCLC, Such as Nonmetastatic Disease, Exon 20 Insertion Mutations and Novel Agents — Helena Yu, MD CME information and select publications…
R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
1 5-Minute Journal Club Issue 4 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer 10:06
Featuring an interview with Dr Seth Wander, including the following topics: Therapy selection after CDK4/6 inhibitor failure: A review of current and investigational treatment for HR-positive, HER2-negative breast cancer Astore S et al. A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors’ failure: A review of current and investigational treatment for HR+/Her2- breast cancer. Crit Rev Oncol Hematol 2024;204:104535. Abstract (0:00) A preoperative window-of-opportunity study of the oral SERD imlunestrant for newly diagnosed ER-positive, HER2-negative localized breast cancer Neven P et al. A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from the EMBER-2 Study. Clin Cancer Res 2024;30(23):5304-13. Abstract (3:30) An assessment of an exosome-based ESR1-monitoring RT-qPCR kit that detects acquired resistance variants in liquid biopsy samples Statt S et al. An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples. ESMO 2024; Abstract 420P . (7:08) CME information and select publications…
R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 1: Management of Metastatic EGFR Mutation-Positive NSCLC — Enriqueta Felip, MD, PhD CME information and select publications
R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
Featuring an interview with Dr Saad Zafar Usmani, including the following topics: Optimizing treatment intervention for patients with newly diagnosed multiple myeloma (MM) (0:00) Role of anti-CD38 antibodies in induction and maintenance therapy for patients with newly diagnosed disease (4:22) Case: A woman in her late 70s with revised International Staging System (R-ISS) Stage II IgG kappa myeloma who received D-Rd followed by maintenance daratumumab (14:02) Case: A man in his early 60s with double-hit myeloma who received D-KRd and carfilzomib maintenance therapy (26:10) Case: A man in his early 70s with R-ISS Stage III IgG kappa myeloma and translocation (4;14) who deferred transplant (33:24) Future directions in the management of MM (40:37) CME information and select publications…
R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
1 Multiple Myeloma — Optimizing the Selection of First-Line Therapy with Dr Saad Zafar Usmani (Companion Faculty Lecture) 28:29
Featuring a slide presentation and related discussion from Dr Saad Zafar Usmani, including the following topics: Evolution of therapeutic decision-making for patients with newly diagnosed multiple myeloma (MM) (0:00) Quadruplet therapy for transplant-eligible patients with newly diagnosed MM (6:26) Daratumumab with lenalidomide as maintenance therapy after transplant in newly diagnosed MM (16:16) Therapeutic options for transplant-ineligible patients with MM (19:51) CME information and select publications…
R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
1 5-Minute Journal Club Issue 3 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer 11:58
Featuring an interview with Dr Seth Wander, including the following topics: The clinical utility of ESR1 mutations in HR-positive, HER2-negative advanced breast cancer Grinshpun A et al. The clinical utility of ESR1 mutations in hormone receptor-positive, HER2-negative advanced breast cancer. Hematol Oncol Clin North Am 2023;37(1):169-81. Abstract (0:00) Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy for ER-positive, HER2-negative advanced breast cancer Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Phase Ia/Ib EMBER study. J Clin Oncol 2024;[Online ahead of print]. Abstract (6:01) EORTC-2129-BCG: Elacestrant for ER-positive/HER2-negative breast cancer patients with ctDNA relapse Ignatiadis M et al. EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA). ESMO 2024; Abstract 338TiP . (8:20) CME information and select publications…
R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
1 Chronic Lymphocytic Leukemia with Dr Jennifer Woyach: Part 3 of a 3-Part Meet The Professor Series 59:28
Featuring perspectives from Dr Jennifer Woyach, including the following topics: AMPLIFY — First-Line Trials Combining Bruton Tyrosine Kinase (BTK) Inhibitors with Venetoclax Introduction (0:00) Case: An African American man in his mid 40s with progressive lymphadenopathy in the neck is diagnosed with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with trisomy 12 and an SF3B1 mutation — Erik Rupard, MD (1:50) Pirtobrutinib Questions for the Faculty: Effectiveness and tolerability of pirtobrutinib for patients with CLL and disease progression on prior BTK inhibition — Zanetta S Lamar, MD (21:18) Choice of First-Line BTK Inhibitor Case: A woman in her mid 80s diagnosed with CLL more than 30 years ago now has relapsed/refractory, ibrutinib-intolerant disease — Warren S Brenner, MD (31:29) Cardiotoxicity of BTK Inhibitors Case: A man in his early 70s with chronic atrial fibrillation requiring long-term anticoagulation is diagnosed with IGHV-unmutated CLL with del(13q), del(17p) and an XPO1 mutation — Bhavana (Tina) Bhatnagar, DO (34:53) Case: A man in his mid 70s with trisomy 12, IGHV-unmutated CLL has a history of congestive heart failure (ejection fraction 20% to 25%) resulting in multiple hospital admissions — Laurie Matt-Amaral, MD, MPH (37:51) CLL and COVID-19 Vaccinations; Role of MRD Testing; Anti-CD20 Antibodies Case: A man in his early 60s with CLL receives first-line obinutuzumab/venetoclax and has a moderate infusion reaction to obinutuzumab — Dr Rupard (41:17) Case: A man in his early 60s with CLL and well controlled autoimmune hemolytic anemia on ibrutinib is switched to zanubrutinib — Dr Lamar (45:26) Questions for the Faculty: CLL and COVID-19 vaccinations; role of MRD testing; anti-CD20 antibodies — Dr Brenner (49:23) Case: An Amish man in his mid 60s requires treatment for CLL but is paying for treatment “out of pocket” — Dr Rupard (55:33) CME information and select publications…
R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
1 Metastatic Triple-Negative Breast Cancer — Oncology Q&A for Clinicians: Discussing Common Questions Posed by Patients 1:00:17
1:00:17
Прослушать Позже
Прослушать Позже
Списки
Нравится
Нравится1:00:17![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Featuring perspectives from Dr Lisa Carey and Dr Rita Nanda, including the following topics: Introduction (0:00) Patient Videos and Clinical Investigator Survey (3:26) San Antonio Breast Cancer Symposium (SABCS®) Report — Education Session on Antibody-Drug Conjugates (26:03) Patient Videos and Clinical Investigator Survey (43:27) SABCS Report — Abstracts of Interest (55:56) Patient Videos and Clinical Investigator Survey (56:27) CME information and select publications…
R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
1 Metastatic Triple-Negative Breast Cancer | Oncology Q&A for Patients with Metastatic Triple-Negative Breast Cancer 1:00:59
1:00:59
Прослушать Позже
Прослушать Позже
Списки
Нравится
Нравится1:00:59![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics: Introduction (0:00) Stages of Triple-Negative Breast Cancer (TNBC); Recurrence After Adjuvant Treatment (5:28) Long-Term Outcomes with Metastatic TNBC (11:55) Side Effects and Complications of Treatment (24:42) Dose Reduction (30:27) Working While Receiving Treatment (32:24) Support for Minor Children and Grandchildren (37:12) Second Opinions and Self Advocacy (42:53) Recording Clinic Visits; Complementary Therapies; Nutrition (48:38) Living Wills and Advanced Directives (55:41) Please take our survey…
R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
1 Lymphoma | What Clinicians Want to Know: Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma 2:00:29
2:00:29
Прослушать Позже
Прослушать Позже
Списки
Нравится
Нравится2:00:29![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie, Prof Martin Hutchings, Dr Matthew Lunning and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Abramson (2:17) Bispecific Antibody Therapy for DLBCL — Prof Hutchings (28:51) CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Lunning (52:01) Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:17:46) Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy — Dr Crombie (1:41:44) CME information and select publications…
R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
1 Myelofibrosis | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Myelofibrosis 1:59:15
1:59:15
Прослушать Позже
Прослушать Позже
Списки
Нравится
Нравится1:59:15![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics: Introduction (0:00) Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Kuykendall (2:53) Managing MF for Patients with Thrombocytopenia — Dr Bose (32:45) Managing MF for Patients with Anemia — Dr Yacoub (59:47) Future Directions in the Management of MF — Dr Fleischman (1:27:53) CME information and select publications…
R
Research To Practice | Oncology Videos
![Research To Practice | Oncology Videos podcast artwork](/static/images/64pixel.png)
1 Metastatic Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of Metastatic Breast Cancer 2:01:00
2:01:00
Прослушать Позже
Прослушать Позже
Списки
Нравится
Нравится2:01:00![icon](https://imagehost.player.fm/icons/general/red-pin.svg)
Featuring perspectives from Dr Erika Hamilton, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O’Shaughnessy and Dr Sara M Tolaney, including the following topics: Introduction (0:00) Optimizing the Care of Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Dr Krop (10:17) Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr Tolaney (37:54) Integrating Novel Agents and Approaches into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Kalinsky (53:59) Tolerability Considerations with Approved and Investigational Antibody-Drug Conjugates — Dr O’Shaughnessy (1:14:16) Other Important Care Considerations for Patients with mBC — Dr Hamilton (1:41:30) CME information and select publications…
Добро пожаловать в Player FM!
Player FM сканирует Интернет в поисках высококачественных подкастов, чтобы вы могли наслаждаться ими прямо сейчас. Это лучшее приложение для подкастов, которое работает на Android, iPhone и веб-странице. Зарегистрируйтесь, чтобы синхронизировать подписки на разных устройствах.